Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2020

Open Access 01-12-2020 | Systemic Lupus Erythematosus | Research article

Systematic review and meta-analysis of clinical outcomes comparison between different initial dialysis modalities in end-stage renal disease patients due to lupus nephritis prior to renal transplantation

Authors: Joel Swai, Xiexiong Zhao, Julie-Raisa Noube, Gui Ming

Published in: BMC Nephrology | Issue 1/2020

Login to get access

Abstract

Background

Regarding lupus disease activity, morbidity and survival, limited literature concluded conflicting results when comparing hemodialysis versus peritoneal dialysis as initial renal replacement therapies (RRT) prior to transplantation, in lupus nephritis end-stage renal disease (LN-ESRD) patients. This study was aimed to compare the risks of lupus flares, all-cause infections, all-cause cardiovascular events, and mortality, between hemodialysis versus peritoneal dialysis as initial RRT - modality before renal-transplant in LN-ESRD patients, by systematic review and meta-analysis.

Methods

PubMed, EMBASE, and SCOPUS were searched for observational-studies comparing LN-ESRD -patients undergoing hemodialysis (Group1) versus peritoneal-dialysis (Group 2) prior to renal-transplantation, by their risks of lupus flare, all-cause infections, all-cause cardiovascular events, and mortality as outcome measures. Relative-Risks of outcomes between the groups measured overall effects at a 95% significance level. RevMan 5.3 computer software was used for analysis.

Results

From search, 16 eligible studies reported 15,636 LN-ESRD -patients prior to renal transplantation with 4616 patients on hemodialysis, 2089 on peritoneal dialysis, 280 directly underwent kidney transplantation, 8319 were eliminated with reasons and 332 participants’ details were not reported. Hemodialysis group had higher risk of all-cause cardiovascular events, Relative-Risk = 1.44 (Confidence Interval:1.02, 2.04), p-Value< 0.05. With regards to risks for mortality, flare and all-cause infections, there were trends that were not statistically significant (p-Value> 0.05).

Conclusion

Except for all-cause cardiovascular events in which peritoneal dialysis is superior to hemodialysis offering better outcomes, both treatment modalities offer more or less similar clinical outcomes as effective initial choices of RRT in LN-ESRD patients prior to renal transplant.

The protocol registration

PROSPERO 2019 CRD42019131600.
Literature
1.
2.
Finzel S, Schaffer S, Rizzi M, Voll RE. Pathogenesis of systemic lupus erythematosus. Z Rheumatol. 2018;77(9):789–98.PubMedCrossRef
3.
Klein A, Polliack A, Gafter-Gvili A. Systemic lupus erythematosus and lymphoma: incidence, pathogenesis and biology. Leuk Res. 2018;75:45–9.PubMedCrossRef
4.
5.
Cameron JS. Lupus nephritis. J Am Soc Nephrol. 1999;10(2):413–24.PubMed
6.
Gõmez-Puerta JA, Feldman CH, Alarcõn GS, Guan H, Winkelmayer WC, Costenbader KH. Racial and ethnic differences in mortality and cardiovascular events among patients with end-stage renal disease due to lupus nephritis. Arthritis Care Res. 2015;67(10):1453–62.CrossRef
7.
Banfi G, Leoni A, Moroni G. Treatment of lupus nephritis associated with end-stage renal disease. G Ital Di Nefrol. 2008;25(Suppl 44):S68–75.
8.
Plantinga LC, Drenkard C, Patzer RE, Klein M, Kramer MR, Pastan S, et al. Sociodemographic and geographic predictors of quality of care in United States patients with end-stage renal disease due to lupus nephritis. Arthritis Rheum. 2015;67(3):761–72.CrossRef
9.
Devlin A, Waikar SS, Solomon DH, Lu B, Shaykevich T, Alarcón GS, et al. Variation in initial kidney replacement therapy for end-stage renal disease due to lupus nephritis in the United States. Arthritis Care Res. 2011;63(12):1642–53.CrossRef
10.
O’Shaughnessy MM, Montez-Rath ME, Lafayette RA, Winkelmayer WC. Patient characteristics and outcomes by GN subtype in ESRD. Clin J Am Soc Nephrol. 2015;10(7):1170–8.PubMedPubMedCentralCrossRef
11.
Sabucedo AJ, Contreras G. ESKD, transplantation, and Dialysis in lupus nephritis. Semin Nephrol. 2015;35(5):500–8.PubMedCrossRef
12.
13.
Kang SH, Chung BH, Choi SR, Lee JY, Park HS, Sun IO, et al. Comparison of clinical outcomes by different renal replacement therapy in patients with end-stage renal disease secondary to lupus nephritis. Korean J Intern Med. 2011;26(1):60–7.PubMedPubMedCentralCrossRef
14.
Mamatov E, Kocaay AF, Koc MA, Celebi ZK, Sengül S, Keven K, et al. Predictive role of neutrophil Gelatinase-associated Lipocaline in donor-specific antibody-positive and donor-specific antibody-negative renal transplant patients. Transplant Proc. 2015;47(6):1688–91.PubMedCrossRef
15.
Cheigh JS, Stenzel KH. End-stage renal disease in systemic lupus erythematosus. Am J Kidney Dis. 1993;21(1):2–8.PubMedCrossRef
16.
Ntatsaki E, Velo-Garcia A, Vassiliou VS, Salama AD, Isenberg DA. Impact of pre-transplant time on dialysis on survival in patients with lupus nephritis. Clin Rheumatol. 2018;37(9):2399–404.PubMedPubMedCentralCrossRef
17.
Gawlik A, Floege J. Dialysis and transplantation in patients with lupus nephritis. Nieren- und Hochdruckkrankheiten. 2004;33(2):97–103.CrossRef
18.
Mojcik CF, Klippel JH. End-stage renal disease and systemic lupus erythematosus. Am J Med. 1996;101(1):100–7.PubMedCrossRef
19.
Tsai WT, Chang HC, Wang CT, Chiang BL, Lin YT. Long-term outcomes in lupus patients receiving different renal replacement therapy. J Microbiol Immunol Infect = Wei mian yu gan ran za zhi. 2019;52(4):648–53.PubMedCrossRef
20.
Krane NK, Burjak K, Archie M, O'Donovan R. Persistent lupus activity in end-stage renal disease. Am J Kidney Dis. 1999;33(5):872–9.PubMedCrossRef
21.
Chang YS, Liu CJ, Wu TH, Chaou CH, Lin KC, Ou SM, et al. Survival analysis in systemic lupus erythematosus patients on maintenance dialysis: a nationwide population-based study in Taiwan. Rheumatol. 2013;52(1):166–72.CrossRef
22.
Weng CH, Hsu CW, Yu CC, Yen TH, Yang CW, Hung CC. Peritoneal dialysis and hemodialysis in systemic lupus erythematosus patients: comparison of clinical outcomes. Kidney Blood Press Res. 2009;32(6):451–6.PubMedCrossRef
23.
Wu MJ, Lo YC, Lan JL, Yu TM, Shu KH, Chen DY, et al. Outcome of lupus nephritis after entering into end-stage renal disease and comparison between different treatment modalities: a nationwide population-based cohort study in Taiwan. Transplant Proc. 2014;46(2):339–41.PubMedCrossRef
24.
Contreras G, Pagan J, Chokshi R, Virmani S, Diego JM, Byers P, et al. Comparison of mortality of ESRD patients with lupus by initial dialysis modality. Clin J Am Soc Nephrol. 2014;9(11):1949–56.PubMedPubMedCentralCrossRef
25.
26.
Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6(7):e1000097.PubMedPubMedCentralCrossRef
27.
Wilhelmus S, Bajema IM, Bertsias GK, Boumpas DT, Gordon C, Lightstone L, et al. Lupus nephritis management guidelines compared. Nephrol Dial Transplant. 2015;31(6):904–13.PubMedCrossRef
28.
Kidney Disease. Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2013;3:1–150.CrossRef
29.
Katalinić L, Eliasson E, Bubić-Filipi L, Kes P, Anić B, Bašić-Jukić N. Renal transplantation in patients with lupus nephritis. Lijec Vjesn. 2014;136(7–8):219–23.PubMed
30.
Goo YS, Park HC, Choi HY, Kim BS, Park YB, Lee SK, et al. The evolution of lupus activity among patients with end-stage renal disease secondary to lupus nephritis. Yonsei Med J. 2004;45(2):199–206.PubMedCrossRef
31.
Stock GG Jr, Krane NK. Treatment of end-stage renal disease due to lupus nephritis: comparison of six patients treated with both peritoneal and hemodialysis. Adv Perit Dial Conf Perit Dial. 1993;9:147–51.
32.
Zhu M, Yan Y, Ni Z, Qian J. Comparison of two-year outcome in maintenance dialysis lupus nephritis patients. Hemodial Int. 2009;13(3):385–6.
33.
Zhang L, Lee G, Liu X, Pascoe EM, Badve SV, Boudville NC, et al. Long-term outcomes of end-stage kidney disease for patients with lupus nephritis. Kidney Int. 2016;89(6):1337–45.PubMedCrossRef
34.
Levy B, Couchoud C, Rougier JP, Jourde-Chiche N, Daugas E. Outcome of patients with systemic lupus erythematosus on chronic dialysis: an observational study of incident patients of the French National Registry 2002-2012. Lupus. 2015;24(10):1111–21.PubMedCrossRef
35.
Mustapic Ž, Puretic Z, Slavicek J, Frkovic M, Jelusic M. Outcome of pediatric patients with end stage renal disease secondary to systemic lupus erythematosus in Croatia in the last four decades. Ann Rheum Dis. 2013;71(3):707.
36.
Kang SH, Hwang HS, Hyoung BJ, Lee SY, Jeon YJ, Chung BH, et al. Comparison of clinical outcome according to different renal replacement therapy in end-stage renal disease patients with lupus nephritis. Am J Transplant. 2010;10:520.
37.
Oliveira CS, D'Oliveira I, Bacchiega ABS, Klumb EM, Albuquerque EMM, Souza E, et al. Renal transplantation in lupus nephritis: a Brazilian cohort. Lupus. 2012;21(5):570–4.PubMedCrossRef
38.
Lee PT, Fang HC, Chen CL, Chiou YH, Chou KJ, Chung HM. Poor prognosis of end-stage renal disease in systemic lupus erythematosus: a cohort of Chinese patients. Lupus. 2003;12(11):827–32.PubMedCrossRef
39.
Plantinga LC, Patzer RE, Drenkard C, Kramer MR, Klein M, Lim SS, et al. Association of time to kidney transplantation with graft failure among U.S. patients with end-stage renal disease due to lupus nephritis. Arthritis Care Res. 2015;67(4):571–81.CrossRef
40.
E. Cimochowski G, Worley E, E Rutherford W, Sartain J, Blondin J, Harter H. Superiority of the Internal Jugular over the Subclavian Access for Temporary Dialysis 1990. 154–161 p.
41.
Oguzkurt L, Tercan F, Torun D, Yildirim T, Zümrütdal A, Kizilkilic O. Impact of short-term hemodialysis catheters on the central veins: a catheter venographic study. Eur J Radiol. 2004;52(3):293–9.PubMedCrossRef
42.
Schwab SJ, Quarles LD, Middleton JP, Cohan RH, Saeed M, Dennis VW. Hemodialysis-associated subclavian vein stenosis. Kidney Int. 1988;33(6):1156–9.PubMedCrossRef
43.
Battistella C, Quattrin R, Celotto D, d'Angelo M, Fabbro E, Brusaferro S, et al. Factors predicting influenza vaccination adherence among patients in dialysis: an Italian survey. Human Vacc Immunother. 2019;15(10):2434–9.CrossRef
44.
Bieber S, Mehrotra R. Peritoneal Dialysis access associated infections. Adv Chronic Kidney Dis. 2019;26(1):23–9.PubMedCrossRef
45.
Soi V, Daifi C, Yee J, Adams E. Pathophysiology and treatment of hepatitis B and C infections in patients with end-stage renal disease. Adv Chronic Kidney Dis. 2019;26(1):41–50.PubMedCrossRef
46.
Viron C, Lobbedez T, Lanot A, Bonnamy C, Ficheux M, Guillouet S, et al. Simultaneous Removal And Reinsertion of the PD Catheter in Relapsing Peritonitis. Perit Dial Int. 2019;39(3):282–8.PubMedCrossRef
47.
Sires RL, Adler SG, Louie JS, Cohen AH. Poor prognosis in end-stage lupus nephritis due to nonautologous vascular access site associated septicemia and lupus flares. Am J Nephrol. 1989;9(4):279–84.PubMedCrossRef
48.
Holley JL, Piraino BM. Complications of Peritoneal Dialysis: Diagnosis and Management. Semin Dial. 1990;3(4):245–8.CrossRef
49.
Althaf MM, Abdelsalam MS, Alsunaid MS, et al. Brevibacterium casei isolated as a cause of relapsing peritonitis. Case Reports. 2014;2014:bcr2014203611.
50.
González-Pulido C, Croca S, Abrol E, Isenberg DA. Long-term activity index after renal failure in a cohort of 32 patients with lupus nephritis. Clin Exp Rheumatol. 2014;32(3):301–7.PubMed
51.
Maroz N, Segal MS. Lupus nephritis and end-stage kidney disease. Am J Med Sci. 2013;346(4):319–23.PubMedCrossRef
52.
Althaf MM, Abdelsalam MS, Alfurayh OI. Lupus flares in two established end-stage renal disease patients with on-line hemodiafiltration during pregnancy - case series. Lupus. 2014;23(9):945–8.PubMedCrossRef
53.
Sekkarie MA, Port FK, Wolfe RA, Guire K, Humphrys R, Van Amburg G, et al. Recovery from end-stage renal disease. Am J Kidney Dis. 1990;15(1):61–5.PubMedCrossRef
54.
Blaizot S, Herzog SA, Abrams S, Theeten H, Litzroth A, Hens N. Sample size calculation for estimating key epidemiological parameters using serological data and mathematical modelling. BMC Med Res Methodol. 2019;19(1):51.PubMedPubMedCentralCrossRef
55.
Nordgren R. Calculating a sample size for a study with repeated measures. J Mol Cell Cardiol. 2019;133:217–9.PubMedCrossRef
56.
Raseta M, Bazarova A. Comments on “a general approach for sample size calculation for the three-arm ‘gold standard’ non-inferiority design”. Stat Med. 2019;38(7):1300–2.PubMedCrossRef
57.
Blome C, Augustin M. Measuring change in quality of life: bias in prospective and retrospective evaluation. Value Health. 2015;18(1):110–5.PubMedCrossRef
58.
Kraft P, Thomas DC. Bias and efficiency in family-based gene-characterization studies: conditional, prospective, retrospective, and joint likelihoods. Am J Hum Genet. 2000;66(3):1119–31.PubMedPubMedCentralCrossRef
Metadata
Title
Systematic review and meta-analysis of clinical outcomes comparison between different initial dialysis modalities in end-stage renal disease patients due to lupus nephritis prior to renal transplantation
Authors
Joel Swai
Xiexiong Zhao
Julie-Raisa Noube
Gui Ming
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2020
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-020-01811-y

Other articles of this Issue 1/2020

BMC Nephrology 1/2020 Go to the issue

Case report

Delayed diagnoses of mitochondrial cytopathies in patients presenting with end stage kidney disease: two case reports

Case report

Atypical presentation of acute post-infectious glomerulonephritis in patients with sickle cell disease: report of two cases

Research article

Patterns and characteristics of cognitive functioning in older patients approaching end stage kidney disease, the COPE-study

Research article

The relative importance of frailty, physical and cardiovascular function as exercise-modifiable predictors of falls in haemodialysis patients: a prospective cohort study

Research article

Genetic variation implicates plasma angiopoietin-2 in the development of acute kidney injury sub-phenotypes

Research article

Global diastolic strain rate for the assessment of left ventricular diastolic dysfunction in young peritoneal dialysis patients: a case control study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits